Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults
Latest Information Update: 16 Jun 2023
Price :
$35 *
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 01 Jun 2023 Status changed from active, no longer recruiting to completed according to results published in the AIDS.
- 01 Jun 2023 Results assessing impact of an additional boost to the RV144 vaccine regimen on antibody effector function and durability published in the AIDS
- 25 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Dec 2021.